Results 251 to 260 of about 55,236 (336)

Desensitization Strategies in Immunized Heart Transplant Recipients.

open access: yesEur Surg Res
Goerler A   +8 more
europepmc   +1 more source

Engineering Innate Immunity: Recent Advances and Future Directions for CAR-NK and CAR-Macrophage Therapies in Solid Tumors. [PDF]

open access: yesCancers (Basel)
Amoozgar B   +9 more
europepmc   +1 more source

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

open access: yesAdvanced Science, EarlyView.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He   +17 more
wiley   +1 more source

LIMD2 is associated with an exhausted CD8⁺ T cell state linked to ICI response in clear cell renal cell carcinoma. [PDF]

open access: yesSci Rep
Zhang J   +11 more
europepmc   +1 more source

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

open access: green, 2008
F. Stephen Hodi   +19 more
openalex   +1 more source

Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome

open access: yesAdvanced Science, EarlyView.
Pharmacological SUMOylation inhibition (SUMOi) counteracts tumor immune evasion by unmasking an immunogenic HLA‐I peptide and neoepitope repertoire. By restoring HLA‐I ligand availability through increased antigen processing and presentation, enhanced proteasomal cleavage, and modulated TAP1 peptide affinity, SUMOi boosts tumor immunogenicity ...
Uta M. Demel   +19 more
wiley   +1 more source

Carbon dot-lipidoid nanocarriers for superiorly biocompatible nasal mRNA cancer vaccination. [PDF]

open access: yesJ Nanobiotechnology
Kim H   +7 more
europepmc   +1 more source

rWTC‐MBTA Vaccine, Alone and Enhanced with Anti‐PD1, Elicits Immune Responses against CNS and Peripheral B‐Cell Lymphoma

open access: yesAdvanced Science, EarlyView.
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy